Menu
Your Cart

Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit (4mL x 384 preps, Standard Edition)

Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit (4mL x 384 preps, Standard Edition)
Secured Shopping
Best security features
Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit (4mL x 384 preps, Standard Edition)

Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit (Standard Edition) (4mL x 384 preps)

  • Powered by Apostle MiniMax technology, Apostle MiniMax High Efficiency cfDNA Isolation Kit is an excellent tool for the isolation of ultra-low concentration cell free DNA (cfDNA). 
  • The superb performance of Apostle MiniMax High Efficiency Cell-Free DNA Isolation Kit has been extensively validated.  Please review the examples of publications and performance data at: https://apostlebio.com/index.php?route=information/information&information_id=15 
  • Configuration: for 384 preps (processing 4 mL plasma each).
  • Cat #: A17622-1536.


Documentation:

Material Safety Data Sheet (MSDS):  https://www.apostlebio.com/minimax/minimax_material_safety_02.pdf


Protocol (manual):  https://www.apostlebio.com/minimax/minimax_protocol_v35_4x384_preps.pdf

Protocol (automated): https://www.apostlebio.com/doc/MagTouch-2000-cfDNA-extraction-2mL-4mL-plasma-protocol.pdf   

This product can be automated on an Apostle MagTouch Nucleic Acid Extraction Automation System, for details of the system, visit: https://apostlebio.com/index.php?route=product/category&path=59


For more information, visit: https://apostlebio.com/index.php?route=information/information&information_id=15 


This product series is also offered through Beckman Coulter Life Sciences.  Please visit the webpage below if you wish to order through Beckman Coulter:

https://www.beckman.com/reagents/genomic/dna-isolation/from-plasma 


$2,700.45
Nature Communications just published a clinical study, including 2125 cancer patients, 9 cancer types, using the Apostle Minimax cfDNA technology. This study demonstrates the ability of its model to detect early-stage cancers using cfDNA, including those of pancreatic origin, with high sensitivity that is comparable to that of late-stage detection. Congratulations to this clinical research team. To date, the Apostle Minimax cfDNA technology has been used in 2 articles published in Nature Medicine, 1 in Nature Communications, 1 in Science Translational Medicine, 1 in PNAS, and over 50 scientific articles in different journals.